Medico Intercontinental Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison
Medico Intercontinental Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison
Last Updated on: May 04, 2026
Key Highlights
The Latest Trading Price of Medico Intercontinental Ltd is ₹ 24.04 as of 30 Apr 15:30
. The P/E Ratio of Medico Intercontinental Ltd changed from 23 on March 2023 to 6.1 on March 2022 . This represents a CAGR of -23.31% over 5 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 years The Market Cap of Medico Intercontinental Ltd changed from ₹ 82.94 crore on March 2023 to ₹ 18.89 crore on March 2022 . This represents a CAGR of -25.61% over 5 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Medico Intercontinental Ltd for the Dec '25 is ₹ 20.19 crore as compare to the Sep '25 revenue of ₹ 20.95 crore. This represent the decline of -3.63% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of Medico Intercontinental Ltd for the Dec '25 is ₹ 1.93 crore as compare to the Sep '25 ebitda of ₹ -0.33 crore. This represent the decline of -684% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of Medico Intercontinental Ltd changed from ₹ 1.08 crore to ₹ -1.68 crore over 7 quarters. This represents a CAGR of NaN%
The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57%
The Dividend Payout of Medico Intercontinental Ltd changed from 5.88 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Medico Intercontinental Ltd
Medico Intercontinental Limited, formerly known as Intercontinental Leasing & Finance Company Limited was incorporated on August 14, 1984 in Ahmedabad, India.
The Company changed its name to 'Medico Intercontinental Limited' in December, 2018.
The Company is involved in trading of pharmaceutical products.
The Company is also providing a platform to all research based bio-pharmaceutical companies reaching their novel and innovative therapies to every part of the globe.
From helping people obtain their medications to using cutting-edge scientific technology to discover new treatments, Medico's entrepreneurial spirit, teamwork-oriented culture and commitment to rare diseases create a unique platform for transforming patient outcomes.
The Company's commitment to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first across the continents.
About Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS).
Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.
FAQs for the comparison of Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd
Which company has a larger market capitalization, Medico Intercontinental Ltd or Sun Pharma Advanced Research Company Ltd?
Market cap of Medico Intercontinental Ltd is 24 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 4,635 Cr
What are the key factors driving the stock performance of Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd?
The stock performance of Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd?
As of May 4, 2026, the Medico Intercontinental Ltd stock price is INR ₹24.04. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹142.85.
How do dividend payouts of Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd compare?
To compare the dividend payouts of Medico Intercontinental Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.